Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli

Blood

Volumn 95, Issue 4, 2000, Pages 1117-1123

  Minnema, M C ^a   Chang, A C K ^b   Jansen, P M ^b   Lubbers, Y T P ^b   Pratt, B M ^b   Whittaker, B G ^b   Taylor, F B ^b   Hack, C E ^b   Friedman, B ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ANTITHROMBIN III;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BABOON; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ESCHERICHIA COLI; FEMALE; FIBRINOLYSIS; HEMODYNAMIC MONITORING; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

EID: 0034651773     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1117.002k12_1117_1123     Document Type: Article

References (23)

1. Bauer KA, Rosenberg RD. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol. 1991;28:10-18.
2. Niessen RW, Lamping RJ, Jansen PM, et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost. 1997;78:1088-1092.
3. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia Coli infusion in baboons. Circ Shock. 1988;26:227-235.
4. Taylor FB, Chang ACK, Peer GT, et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood. 1991;78: 364-368.
5. Levi M, van der Poll T, ten Cate H, van Deventer SJH. The cytokine-mediated imbalance between coagulation and anticoagulation mechanisms in sepsis and endotoxemia. Eur J Clin Invest. 1997: 27:3-9.
6. Edmunds T, van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood. 1998;91: 4561-4571.
7. Taylor FB, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918-925.
8. Jansen PM, Eisele B, de Jong IW, et al. Effect of C1-inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol. 1998;160:475-484.
9. Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with new chromogenic substrates (S-2238 and Chromozym TH). Thromb Res. 1977;11:549-553.
10. Helle M, Boeije L, de Groot ER, de Groot A, Aarden LA. Sensitive ELISA for interleukin-6: detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods. 1991;38:47-56.
11. Jansen PM, van Damme J, Put W, de Jong IW, Taylor FB, Hack CE. Monocyte chemotactic protein 1 (MCP-1) is released during lethal and sublethal bacteremia in baboons. J Infect Dis. 1995; 171:1640-1642.
12. van der Pouw Kraan TC, Boeije L, Smeenk RJT, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin-12 production. J Exp Med. 1995;181:775-779
13. Jansen PM, Pixley RA, Brouwer M, et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood. 1996;87:2337-2344.
14. Boermeester MA, van Leeuwen PA, Coyle SM, Wolbink GJ, Hack CE, Lowry SF. Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg. 1995;130:739-748.
15. de Boer JP, Creasey AA, Chang A, et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia Coli. Circ Shock. 1993;39:59-67.
16. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66:835-839.
17. van der Poll T, Jansen PM, Montegut, et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol. 1997;158:1971-1975.
18. Jansen PM, van der Pouw Kraan TC, de Jong IW, et al. Release of 11-12 in experimental Escherichia Coli septic shock in baboons: relation to plasma levels of Interleukin-10 and Interteron-y. Blood. 1996;87:5144-5151.
19. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989;170:1627-1633.
20. Spannagl M, Hoffmann H, Siebeck M, Weipert J, Schwarz HP, Schramm W. A purified antithrombin III - heparin complex as a potent inhibitor of thrombin in porcine endotoxin shock. Thromb Res. 1991;61:1-10.
21. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost. 1993;69:98-102.
22. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood. 1997;89:4393-4401.
23. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost. 1998;24:27-32.